Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection.

BACKGROUND: Multiple first-line immune checkpoint regimens are approved for advanced melanoma, yet no biomarker reliably guides their selection. LAG-3, an inhibitory checkpoint enriched on exhausted immune cells, may reflect tumor-immune state beyond PD-L1 and guide therapeutic decisions. METHODS: We retrospectively analyzed Tempus platform data . Among 2,177 patients with advanced melanoma and RNA sequencing, 145 received first-line PD-1 monotherapy and 222 CTLA-4/PD-1 combination. LAG3 and CD274 (PD-L1) transcript levels were evaluated as dichotomous variables. Outcomes included objective response rate (ORR) at 90 days and real-world overall survival (rwOS). We assessed treatment-biomarker (LAG3/CD274) interactions and performed statistical de-correlation and fit treatment-specific multivariable Cox models including LAG3 expression, CD274 expression, and estimated CD8 T-cell infiltration . We also explored LAG3 association with immune infiltrate, tumor mutation - and neoantigen-burdens. RESULTS: Under monotherapy, high LAG-3 was associated with improved outcomes, ORR (67% vs 15%, p = 0.002); risk of death (HR 0.64; p < 0.001). In contrast, ORR and risk of death were similar for the combination cohort regardless of LAG-3 expression (HR 0.94, p = 0.6). After de-correlation, LAG-3 retained significant association with rwOS under monotherapy, whereas the association for CD274 was attenuated, indicating non-redundant biomarker information. In multivariable Cox analysis including continuous LAG3, CD274, and estimated CD8 T-cell infiltration, LAG3 remained independently associated with improved rwOS in the PD-1 monotherapy cohort (HR 0.54, 95% CI 0.32-0.91; p = 0.021), whereas neither CD274 nor CD8 infiltration remained significant. No biomarker significantly discriminated outcomes within the combination therapy cohort. CONCLUSIONS: These findings support further validation of LAG3 RNA expression as a candidate biomarker for frontline immunotherapy selection in advanced melanoma.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-12
DOI
https://doi.org/10.1093/oncolo/oyag441
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection.

Inderjit Mehmi, Jacob Mercer, Unnati Jariwala, Adam Joseph Dugan et al.
PubMed
Cancer Immunotherapy and Biomarkers
article

Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection.

Inderjit Mehmi, Jacob Mercer, Unnati Jariwala, Adam Joseph Dugan, Stamatina Fragkogianni, Binyam Yilma, Kathryn Blount Bollin, Siwen Hu‐Lieskovan, Omid Hamid, Jonathan E Cohen
article en

Abstract

BACKGROUND: Multiple first-line immune checkpoint regimens are approved for advanced melanoma, yet no biomarker reliably guides their selection. LAG-3, an inhibitory checkpoint enriched on exhausted immune cells, may reflect tumor-immune state beyond PD-L1 and guide therapeutic decisions. METHODS: We retrospectively analyzed Tempus platform data . Among 2,177 patients with advanced melanoma and RNA sequencing, 145 received first-line PD-1 monotherapy and 222 CTLA-4/PD-1 combination. LAG3 and CD274 (PD-L1) transcript levels were evaluated as dichotomous variables. Outcomes included objective response rate (ORR) at 90 days and real-world overall survival (rwOS). We assessed treatment-biomarker (LAG3/CD274) interactions and performed statistical de-correlation and fit treatment-specific multivariable Cox models including LAG3 expression, CD274 expression, and estimated CD8 T-cell infiltration . We also explored LAG3 association with immune infiltrate, tumor mutation - and neoantigen-burdens. RESULTS: Under monotherapy, high LAG-3 was associated with improved outcomes, ORR (67% vs 15%, p = 0.002); risk of death (HR 0.64; p < 0.001). In contrast, ORR and risk of death were similar for the combination cohort regardless of LAG-3 expression (HR 0.94, p = 0.6). After de-correlation, LAG-3 retained significant association with rwOS under monotherapy, whereas the association for CD274 was attenuated, indicating non-redundant biomarker information. In multivariable Cox analysis including continuous LAG3, CD274, and estimated CD8 T-cell infiltration, LAG3 remained independently associated with improved rwOS in the PD-1 monotherapy cohort (HR 0.54, 95% CI 0.32-0.91; p = 0.021), whereas neither CD274 nor CD8 infiltration remained significant. No biomarker significantly discriminated outcomes within the combination therapy cohort. CONCLUSIONS: These findings support further validation of LAG3 RNA expression as a candidate biomarker for frontline immunotherapy selection in advanced melanoma.

PubMed
Hebrew University of Jerusalem (IL), Hadassah Medical Center (IL), Huntsman Cancer Institute (US), Angeles Clinic and Research Institute (US), Tempus Labs (United States) (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon